Full Title
A Phase Ib/II, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid TumorsPurpose
Researchers want to find the best dose of ZL-1310 to use in people with advanced digestive tumors. The people in this study have gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) that spread and keeps growing after treatment. These tumors include NEC of the esophagus, stomach, pancreas, gallbladder, or colon/rectum.
ZL-1310 is an antibody-drug conjugate (ADC). ADCs are substances made of an antibody linked to a cancer-fighting drug. The antibody binds to specific proteins on cells, including cancer cells. The linked drug enters these cells and kills them, with a reduced risk of harming other cells.
ZL-1310 may work well against your cancer because it targets cells with a protein called DLL3. This protein is found on the surface of certain cancer cells and plays a role in cancer cell growth. By destroying these cells, ZL-1310 may help slow or stop the growth of your cancer. It is given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You must:
- Have GEP NEC that spread and keeps growing after no more than 2 prior regimens of treatment.
- Have recovered from the serious side effects of previous therapies before getting ZL-1310.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information and to see if you can join this study, please call Dr. Rohit Thummalapalli’s office at 646-888-4494.